The First Triple Agonist in Metabolic Research
Retatrutide (LY-3437943) represents a paradigm shift in incretin-based research. As the first compound to simultaneously activate GLP-1, GIP, and glucagon receptors, it opens entirely new research pathways that single or dual agonists cannot address.
Why Triple Agonism Matters
Each receptor adds a distinct metabolic mechanism: GLP-1 controls appetite and insulin, GIP enhances energy expenditure, and glucagon drives hepatic fat oxidation and thermogenesis. The synergistic activation of all three creates the most comprehensive metabolic intervention studied to date.
Phase 2 Trial Highlights
The landmark phase 2 trial published in the New England Journal of Medicine demonstrated that retatrutide at the 12mg dose produced the most significant body composition changes of any incretin-based compound in clinical history. The dose-response curve was clear across all dose cohorts.
Comparison with Predecessors
The evolution from semaglutide (single) to tirzepatide (dual) to retatrutide (triple) represents an increasingly comprehensive approach to metabolic pathway activation. See our triple comparison guide.
Phase 3 Outlook
Phase 3 trials (TRIUMPH program) are underway with results expected to further characterize retatrutide’s long-term safety and efficacy profile.
See dosage guide and complete research guide.
For research purposes only. Catalog | COAs